Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 trial to evaluate the safety and efficacy of the specific immunotherapy, recombinant idiotype conjugated to KLH [keyhole limpet haemocyanin] (GTOP 99) with GM-CSF [granulocyte-macrophage colony-stimulating factors], compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma

Next Previous
X
Search
Trial Profile

A phase 3 trial to evaluate the safety and efficacy of the specific immunotherapy, recombinant idiotype conjugated to KLH [keyhole limpet haemocyanin] (GTOP 99) with GM-CSF [granulocyte-macrophage colony-stimulating factors], compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2008

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GTOP 99 (Primary)
  • Indications B-cell lymphoma; Follicular lymphoma
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 09 May 2008 Status change
    • 16 Apr 2008 Status change from in progress to completed
    • 16 Apr 2008 Results presented at AACR in 2008

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top